Phenotyping Like Never Before.
INTRODUCING
The next generation immunoassay.
PhenoDot and the Future of Immunoassay Technology
At Elleon Biotech we’re redefining what is possible with immuno-assay technology. Our patent pending next generation immunoassays enables new avenues of research and understanding, unlocking new treatments, cures, and diagnostics.
Why is PhenoDot so important?
In the aftermath of COVID-19 there has been great emphasis on our industry to improve and develop vaccines, treatments, and tools that will help us respond more quickly and greatly reduce the risk to life of a “Disease X” outbreak.
These are both challenging and exciting times for healthcare and biosciences and Elleon Biotech with our PhenoDot technology are setting ourselves to be part of the evolution of healthcare coming out of the COVID-19 pandemic.
Who is calling for action and what do they need?
World Health Organisation.
“In addition to considering speed and cost, preparation for the next pandemic must consider QUALITY, EQUITY, and TRUST as essential values.”
Philip Krause (key advisor to the WHO)
Coalition for Epidemic Preparedness Innovations.
“We don’t know when or where the next Disease X will strike, only that it will. CEPI is advancing global R&D efforts so the world is better prepared to tackle a Disease X, within 100 days of its identification."
United Kingdom Health Security Association (UKHSA).
Some of the targets over the coming years for UKHSA include
““1. Be ready to respond to all hazards to health.
to prevent and mount scalable and agile responses to health security threats, including pandemics.”
“2. Improve health outcomes through vaccines.
to facilitate innovation in the development of safe and effective vaccines.”
”3. Reduce the impact of infectious diseases and antimicrobial resistance.
minimise the impact of infectious disease”
So what is PhenoDot?
PhenoDot is the next generation in immunoassay technology, combining and building on the strengths of systems like ELISpot and FACS. PhenoDot enables simultaneous detection of both cell surface and secretion markers in a single assay for faster, cheaper, and more accurate phenotyping. Similar in style to an ELISpot assay but with more selection possibilities, we can maintain cell viability, and reduce assay costs.
Elleon Biotech are proud to be supported by Hong Kong Productivity Council (HKPC) & the Innovation and Technology Commission (ITC) with patent application grant (PAG) funding for our patent pending PhenoDot technology.
How can PhenoDot make a difference?
More accurate
Directly identify a cell by multiple markers including both cell surface and secretion markers and positively pick them without further sorting. PhenoDot removes the assumptions made with current techniques relying on different assays to identify different marker types and removes the assumptions comparing the data. For example PhenoDot could be the next step in vaccine development offering a way to determine conference of long term immunity by identifying cells by unique surface marker, binding of the antigen for example the vaccine or pathogen fragment, and a secretion response to the binding.
Faster
By detecting multiple markers in a single assay we can greatly reduce testing times, and without relying on cell differentiation and inter assay comparison studies we can further reduce time and cost. For example PhenoDot can perform the cell surface marker identification and sorting offered by FACS and at the same time identify secretion markers like an ELISpot assay performed at the same time in a single test. Taking identification of a cell for cloning for example we can vastly reduce times for achieving a monoclonal cell line by performing positive identification in fewer steps with fewer depletions and growth cycles.
Reduced costs
Focusing on low technological requirements, PhenoDot is a system with minimal setup cost, reducing the barrier to entry, for tests which might otherwise be cost prohibitive. This means new possibilities for clinics, hospitals, new researchers, for example who may not have the budget for equipment as required for flow cytometry and FACS to carry out their testing. Such reduction in costs offers far greater opportunities for accumulation of data from far broader scope of samples, these could feed into better drug development or vaccine development for example. Additionally reducing costs allows for testing and research to be carried out in lower income countries or those with lower healthcare budgets.
Flexibility
So many possible use cases mean PhenoDot can help achieve the future world goals in many ways, from early vaccine candidate selection, to dose and booster regime study, to development of treatments such as immunotherapies, and production of antibodies in detection, research and treatment of infectious diseases. Platforms for testing can be changed according to sample size needs, there are applications also in microbiology for example bacteria identification or detection of contamination, and a whole wealth of opportunities we’ve barely started to scratch the surface.
Elleon Biotech
Discover our journey our drive and motivation in innovation of immuno-assay technology, ensuring a brighter future for scientific advancement and public welfare. Pioneering solutions in vaccine development to cutting-edge diagnostics and state-of-the-art biocleanliness products, we are here to build a healthier future for all.
